<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292536</url>
  </required_header>
  <id_info>
    <org_study_id>HCI103657</org_study_id>
    <nct_id>NCT03292536</nct_id>
  </id_info>
  <brief_title>Merestinib on Bone Metastases in Subjects With Breast Cancer</brief_title>
  <official_title>An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open label, pharmacodynamics, intrapatient dose escalation phase 1B
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>a single arm, open label, pharmacodynamics, intrapatient dose escalation phase 1B study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events that Occur</measure>
    <time_frame>12 weeks, checked at every visit in that time period</time_frame>
    <description>To assess the tolerability of merestinib in combination with standard breast cancer therapies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in urinary N-telopeptide level</measure>
    <time_frame>12 weeks</time_frame>
    <description>To measure the change in urinary N-telopeptide level after 12 weeks of therapy with merestinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute and percentage change in serum B-CTX, TRAP-5b, P1NP and BSAP</measure>
    <time_frame>12 weeks</time_frame>
    <description>To measure the absolute and percentage change in serum β-CTX, TRAP-5b, P1NP, and BSAP at time points from baseline to 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to skeletal-related events</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate determine time to skeletal-related event(s) following initiation of merestinib dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate change in pain as measured by pain scores during and after 12 weeks of merestinib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain by narcotic use</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate change in pain as measured by narcotic use) during and after 12 weeks of merestinib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone lesion uptake</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the change in bone lesion uptake on NaF PET scan after 12 weeks of merestinib treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Bone Metastases</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Merestinib, all patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Merestinib</intervention_name>
    <description>*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen*
Subjects will receive merestinib 20mg PO QDay (dose level 0) for 2, 3 or 4 weeks (depending on anticancer regimen) followed by 40mg PO Qday (dose level 1) for 2, 3 or 4 weeks followed by 80mg PO daily (dose level 2) for 8, 6 or 4 weeks.</description>
    <arm_group_label>Merestinib, all patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 1 osteolytic bone metastases must be present

          -  Urinary N-telopeptide level above 40nM BCE/mM creatinine measured at ARUP

          -  Archived or freshly biopsied primary and/or bone metastatic tumor tissue available in
             paraffin-embedded blocks or slides that is expected to yield 9 slides

          -  Life expectancy of ≥ 6 months

          -  Toxicity related to prior treatments must either have resolved to grade 1 or less,
             returned to baseline, or be deemed irreversible

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (within 28 days
             prior to enrollment)

          -  Planning to remain on current breast cancer therapy for at least 12 weeks.

          -  At least one prior line of therapy for metastatic breast cancer

          -  Concurrent treatment with bisphosphonates or denosumab is required.

        Exclusion Criteria:

          -  Unable to swallow or take anything orally

          -  ECG abnormalities:

               -  Prolonged QTc (Bazette's or Fredericia's correction) interval on screening ECG (≥
                  450 msec)

               -  QRS ˃ 120 msec

               -  PR ˃ 210 msec

               -  Any prior history, or current evidence of second- or third-degree heart block

               -  Heart rate ˂ 40 beats per minute at screening

               -  ECG second degree heart block (Mobitz's Type 2 or Wenckebach)

               -  Complete heart block

               -  Left bundle branch block or bifascicular block (right bundle branch block and
                  left anterior hemiblock together)

               -  Episodes of ventricular tachycardia

          -  Any known prior malignancy (not including non-melanoma skin cancers), unless treated
             with curative intent

          -  A serious uncontrolled medical disorder or active infection, which would impair the
             ability of the subject to receive protocol therapy

          -  Current or recent (within 3 months) gastrointestinal disease that could impact the
             absorption (i.e., unmanageable diarrhea or malabsorption at the time of screening)

          -  Inadequate bone marrow function defined as:

               -  Absolute neutrophil count (ANC) ˂ 1,500 cells/mm3

               -  Platelet count ˂ 100,000 cells/mm3

               -  Hemoglobin ˂ 9 g/dL

          -  Inadequate hepatic function defined as:

               -  Total bilirubin ˃ 1.5 x institutional upper limit of normal (IULN) (Unless due to
                  diagnosis of Gilbert's Syndrome)

               -  Alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) ˃ 2.5 x
                  IULN

          -  Inadequate renal function defined as: Serum creatinine ˃ 1.5 x ULN

          -  Prothrombin time (PT)/partial thromboplastin time (PTT) ˃ 1.5 times the ULN

          -  Serum sodium, potassium, and calcium levels equivalent to Grade 1 AE values as defined
             by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0

          -  Any atrophic macular condition including intermediate or advanced age-related macular
             degeneration

          -  Patients receiving medications that are known to be substrates of CYP2C8 (including
             paclitaxel), CYP2C9, or CYP2C19 or to be oral substrates of CYP3A with narrow
             therapeutic window (listed on http://medicine.iupui.edu/clinpharm/ddis/main-table).
             Subjects who have discontinued any of these medications must have a wash-out period of
             at least 5 days or 5 half-lives of the drug (whichever is longer) prior to the first
             dose of merestinib

          -  Exposure to any investigational drug or placebo within 4 weeks of enrollment

          -  Any other sound medical, psychiatric, and/or social reasons as determined by the
             investigator

          -  History of diseases with influence on bone metabolism, such as Paget's disease,
             osteogenesis imperfecta, active primary or secondary hyperparathyroidism, and primary
             or secondary hyperthyroidism within 12 months prior to study entry

          -  Patients with known symptomatic brain metastasis. Subjects with controlled brain
             metastasis (no radiographic progression at least 4 weeks following radiation and/or
             surgical treatment and no neurological signs or symptoms) will be allowed

          -  History of allergy to merestinib or chemically related compounds

          -  History of osteonecrosis of the jaw

          -  Change in chemotherapy or hormone therapy within 8 weeks of the start of the study.

          -  Active gout or inflammatory arthritis requiring treatment

          -  Use within 28 days of registration of calcitonin, recombinant parathyroid
             hormone-related peptides, mithramycin, radium, strontium ranelate, or gallium nitrate.

          -  Adult patients who require monitored anesthesia for PET scanning due to
             claustrophobia.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth Constantz</last_name>
    <phone>801-587-4567</phone>
    <email>Elizabeth.Constantz@hci.utah.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Constantz</last_name>
      <phone>801-587-4567</phone>
      <email>Elizabeth.Constantz@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

